NK521 infusion for advanced cancer with fluid buildup
Part of Cancer clinical trials.
This early-stage trial tests NK521, a new immunotherapy infusion, for patients with advanced solid tumors (like liver, stomach, or colon cancer) that have spread and caused fluid buildup in the belly. The goal is to see if NK521 can help shrink tumors and improve survival when standard treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with advanced cancer (relapsed or not responding to treatment) that has spread, with at least two prior lines of standard therapy that did not work
- Your cancer has caused malignant ascites (fluid buildup in the belly) with cancer cells visible in that fluid
- You have at least one measurable tumor visible on CT or MRI scans
- You are able to perform light activities (ECOG performance status 0–2); your life expectancy is at least 3 months
- Any side effects from previous cancer treatments have cleared to mild levels (Grade 1 or less), except hair loss and fatigue
- You do not have active cancer in the brain, other cancers in the past 3 years, untreated autoimmune disease, HIV, or severe heart disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational NK cell therapy (NK042) for people with advanced solid tumors that have not responded to standard treatments. The aim is to see if this cellular therapy is safe and potentially effective.
This trial tests an injection of your own immune cells (tumor-infiltrating lymphocytes) to see if they can fight advanced solid tumors like stomach or lung cancer. Doctors will remove one of your tumors, grow the immune cells from it, and then give them back to you.
This trial tests an investigational natural killer (NK) cell therapy for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if these immune cells can shrink tumors and are safe.
This study tests a new immune cell treatment called EB-NK-301, which are lab-modified natural killer cells designed to attack cancer cells that have a protein called TROP2. The trial is for people with advanced solid tumors (cancers that have spread) whose cancer has stopped responding to standard treatments.
This Phase 1/2 study tests an intravenous (IV) immune-cell therapy made from donors (allogeneic NK cells) to treat advanced solid tumors, relapsed/refractory non-Hodgkin lymphoma, or multiple myeloma. It may help by targeting cancer cells more directly, but early-phase trials mainly focus on safety and finding the right dosing.
This trial tests a new type of therapy where special cells (called SK-NK cells) are injected directly into the belly to treat fluid buildup (ascites) caused by advanced ovarian cancer. It is for patients whose cancer has not responded to at least two prior treatments and who have no other standard options left.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.